Osteoarthritis in 2007.
Osteoarthritis (OA) is often a progressive and disabling disease resulting from a combination of risk factors, including age, genetics, trauma, and knee alignment, as well as an imbalance of physiologic processes resulting in inflammatory cascades on a molecular level. The synovium, bone, and cartilage are each involved in the pathophysiological mechanisms that lead to progressive joint degeneration, and, thus, also serve as targets for therapies. Efforts to identify disease-modifying osteoarthritis drugs (DMOADs) have been hampered by several factors, but the focus has now shifted toward the validation of chemical and imaging biomarkers that should aid in DMOAD development. In this review, we summarize current pathological mechanisms occurring in the individual but interconnected compartments of OA joints, as well as discuss related therapeutic interventions that are currently available or on the horizon.
Krasnokutsky
Svetlana
S
New York University School of Medicine, Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA.
Samuels
Jonathan
J
Abramson
Steven B
SB
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002116:Calcitonin / Q000627:therapeutic use; D002807:Chondroitin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D005944:Glucosamine / Q000627:therapeutic use; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology*
D015415:Biomarkers; D004164:Diphosphonates; D053590:Interleukin 1 Receptor Antagonist Protein; D009569:Nitric Oxide; D002116:Calcitonin; D002807:Chondroitin; D008666:Metalloendopeptidases; D005944:Glucosamine; D004318:Doxycycline